Abstract: Slide Presentations |

Mometasone furoate dry powder inhaler (MF-DPI) improves FEV1, symptoms, and quality of life and reduces exacerbations in patients with COPD FREE TO VIEW

Harold Nelson, MD; Jill P. Karpel, MD; Heribert Staudinger, MD; William W. Busse, MD*
Author and Funding Information

University of Wisconsin, Madison, WI


Chest. 2004;126(4_MeetingAbstracts):709S-c-710S. doi:10.1378/chest.126.4_MeetingAbstracts.709S-c
Text Size: A A A
Published online


PURPOSE:  To compare the efficacy and safety of MF-DPI 800 mcg once daily in the evening (qd PM), MF-DPI 400 mcg bid, and placebo in subjects with COPD not previously treated with inhaled corticosteroids (ICSs).

METHODS:  Subjects (N = 911) >=40 years of age and history of COPD were randomized to 52 weeks of double-blind treatment with MF-DPI 800 mcg qd PM, MF-DPI 400 mcg bid, or placebo. All subjects had >=10 pack-years smoking history, and low bronchodilator reversibility. The primary efficacy variables were changes from baseline in post-bronchodilator FEV1 and total COPD symptom scores, and percentage of subjects with >=1 COPD exacerbation. Secondary efficacy variables included response to therapy evaluations and quality of life assessments. Safety variables were also assessed.

RESULTS:  In subjects using MF-DPI 800 mcg qd PM and MF-DPI 400 mcg bid, post-bronchodilator FEV1 increased from baseline by 50 mL, compared with a 19 mL decrease in the placebo group (P<.001). Subjects using MF-DPI 400 mcg bid had significant 19% reductions in COPD symptom scores (P<.001 vs placebo). For the pooled MF-DPI subjects, the percentage with COPD exacerbations was significantly reduced; the time to first exacerbation was significantly prolonged (P ≤.043 vs placebo); and significant (P ≤.03 vs placebo) quality of life improvements as measured by the St. George’s Respiratory Questionnaire (SGRQ) were observed. The percentage of subjects with COPD exacerbations was significantly (p = .043) reduced, the time to first exacerbation was significantly (p<.02) prolonged, and exacerbation rates were reduced. MF-DPI was well tolerated, with no unusual or unexpected adverse events.

CONCLUSION:  MF-DPI is effective in the treatment of COPD in patients not previously treated with ICSs. Similar effects on lung function and exacerbations are achieved with MF-DPI administered as 800 mcg qd PM and 400 mcg bid. Symptom reduction with 400 mcg bid was not significantly different from that with 800 mcg qd.

CLINICAL IMPLICATIONS:  MF-DPI, administered once daily in the evening, is a useful adjunct in the treatment of COPD.

DISCLOSURE:  W.W. Busse, Schering-Plough Research Institute

Monday, October 25, 2004

10:30 AM- 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543